In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Defining Biopharma Dealmaking Success: An Analysis Of 2003 Alliances

Executive Summary

This article examines the question do external biopharma programs succeed at similar rates as internal projects? IN VIVO examined this question by analyzing the alliances of 2003, mining both Elsevier's Strategic Transactions database and SEC documents, and bolstering these data with independent reporting.

You may also be interested in...



Abbott Becomes Third US TAVR Competitor With Portico Approval

Portico with the FlexNav delivery system earned FDA approval for people with symptomatic, severe aortic stenosis who would be at high or extreme risk in open-heart surgery.

Coronavirus Update: Pfizer/BioNTech Vaccine Shows Antibody Response In Young Kids

The companies announced data from their Phase II/III study in children aged 5-11 and intend to take them to regulators to expand Comirnaty's authorization; also, an expert panel advising India's drug regulator endorsed plans for a Phase III trial of a single-dose Russian vaccine, Sputnik Light.

Back to The Past: The Case for Improving Upon, Not Throwing Out Traditional Cancer Phase I Study Designs

US FDA has pushed sponsors away from the traditional dose-finding designs for cancer drugs in recent years. But academics continue to make a case for keeping the 3+3 design with some improvements.

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV003463

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel